S&P 500   5,088.80
DOW   39,131.53
QQQ   437.51
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.51
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.51
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.51
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound

Bio-Rad Laboratories (BIO) Competitors

$337.99
-0.48 (-0.14%)
(As of 02/23/2024 06:40 PM ET)

BIO vs. WAT, ILMN, BIO.B, RVTY, TXG, AVTR, OLK, UTHR, HSIC, and PEN

Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Waters (WAT), Illumina (ILMN), Bio-Rad Laboratories (BIO.B), Revvity (RVTY), 10x Genomics (TXG), Avantor (AVTR), Olink Holding AB (publ) (OLK), United Therapeutics (UTHR), Henry Schein (HSIC), and Penumbra (PEN). These companies are all part of the "medical" sector.

Bio-Rad Laboratories vs.

Waters (NYSE:WAT) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

In the previous week, Waters had 37 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 51 mentions for Waters and 14 mentions for Bio-Rad Laboratories. Waters' average media sentiment score of 0.91 beat Bio-Rad Laboratories' score of 0.10 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
9 Very Positive mention(s)
10 Positive mention(s)
22 Neutral mention(s)
7 Negative mention(s)
3 Very Negative mention(s)
Neutral
Bio-Rad Laboratories
7 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Waters has a net margin of 21.72% compared to Waters' net margin of -23.86%. Bio-Rad Laboratories' return on equity of 81.30% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters21.72% 81.30% 16.41%
Bio-Rad Laboratories -23.86%3.90%2.77%

Waters received 71 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 65.09% of users gave Bio-Rad Laboratories an outperform vote while only 54.65% of users gave Waters an outperform vote.

CompanyUnderperformOutperform
WatersOutperform Votes
429
54.65%
Underperform Votes
356
45.35%
Bio-Rad LaboratoriesOutperform Votes
358
65.09%
Underperform Votes
192
34.91%

Waters has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.96B6.63$642.23M$10.8530.53
Bio-Rad Laboratories$2.67B3.61-$637.32M-$21.49-15.73

Waters presently has a consensus price target of $293.50, suggesting a potential downside of 11.40%. Bio-Rad Laboratories has a consensus price target of $493.75, suggesting a potential upside of 46.08%. Given Waters' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

94.0% of Waters shares are owned by institutional investors. Comparatively, 64.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.8% of Waters shares are owned by company insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Waters has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Summary

Waters beats Bio-Rad Laboratories on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO vs. The Competition

MetricBio-Rad LaboratoriesAnalytical instruments IndustryMedical SectorNYSE Exchange
Market Cap$9.64B$5.62B$4.81B$17.14B
Dividend YieldN/A0.41%5.40%3.56%
P/E Ratio-15.736.48162.2320.83
Price / Sales3.617.162,987.157.35
Price / Cash27.9273.5324.9516.83
Price / Book1.102.984.485.73
Net Income-$637.32M-$8.68M$107.83M$855.91M
7 Day Performance-0.74%-0.41%113.28%0.95%
1 Month Performance2.64%1.74%121.96%2.73%
1 Year Performance-29.59%1.33%133.61%6.14%

Bio-Rad Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WAT
Waters
2.6016 of 5 stars
$323.94
-0.4%
$293.50
-9.4%
+5.5%$19.23B$2.96B29.868,200
ILMN
Illumina
4.7715 of 5 stars
$140.05
-2.3%
$166.95
+19.2%
-32.3%$22.24B$4.50B-19.0810,260Insider Buying
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$352.91
flat
N/A-16.5%$10.29B$2.67B-16.427,900News Coverage
Gap Down
RVTY
Revvity
3.8543 of 5 stars
$101.98
-0.5%
$118.91
+16.6%
N/A$12.59B$2.75B18.5416,700Analyst Revision
TXG
10x Genomics
4.676 of 5 stars
$47.46
-2.0%
$62.44
+31.6%
-4.4%$5.61B$618.73M-21.871,243
AVTR
Avantor
4.4968 of 5 stars
$24.07
+1.3%
$26.14
+8.6%
-1.1%$16.33B$6.97B50.1514,500
OLK
Olink Holding AB (publ)
0.8355 of 5 stars
$22.74
-7.9%
$22.00
-3.3%
-1.4%$2.83B$139.85M-162.42582Upcoming Earnings
Positive News
High Trading Volume
UTHR
United Therapeutics
4.9912 of 5 stars
$214.16
-0.3%
$292.80
+36.7%
-9.1%$10.06B$1.94B11.80985Earnings Report
Analyst Revision
HSIC
Henry Schein
3.6091 of 5 stars
$75.64
0.0%
$79.25
+4.8%
-1.2%$9.83B$12.65B22.5122,000Upcoming Earnings
PEN
Penumbra
4.8568 of 5 stars
$268.61
-0.7%
$307.25
+14.4%
-10.8%$10.37B$847.13M260.793,900Earnings Report
Analyst Report

Related Companies and Tools

This page (NYSE:BIO) was last updated on 2/26/2024 by MarketBeat.com Staff

From Our Partners